本システムでは、JavaScriptを利用しています。JavaScriptを有効に設定してからご利用ください。
Skip to main content
Contact Us
Accessibility
LANGUAGE
JP
EN
HOME
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Calendar
Management Strategies and Policies
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock and Shareholder Information
Sustainability
Our Sustainability
Environmental
Social
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
About ASKA Pharmaceutical Holdings
Company Overview
Group Companies
Top Message
Corporate Philosophy
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
Management Strategies and Policies
IR News
IR Library
IR Calendar
Governance
Financial Highlights
ASKA Pharmaceutical Holdings at a glance
IR Related Information
Stock & Shareholder Information
Sustainability
Integrated Report (Related links)
Our Basic Policy for Sustainability
Various Contrasting Tables
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Governance (Related links)
External Evaluation
Third-party Opinion
Various Contrasting Tables
Integrated Report (Related links)
Social
ESG Chart and ESG Data Book
Initiatives and Member Organizations
Sustainability News
Policies (Related links)
HOME
>
HOME
>
For Our Shareholders and Investors
>
Financial Highlights
>
Financial Statements
>
Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
PRINT
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
[Based on Japanese GAAP]
Consolidated Statements of Cash Flows
(Unit: millions of yen)
Fiscal year ended
03/31/2025
Fiscal year ended
03/31/2026
Cash flows from operating activities
Profit before income taxes
6,192
6,991
Depreciation
2,247
2,917
Amortization of goodwill
-
168
Impairment losses
300
-
Increase (decrease) in retirement benefit asset and liability
231
(164)
Interest and dividend income
(293)
(391)
Interest expenses
51
222
Foreign exchange losses (gains)
97
189
Share of loss (profit) of entities accounted for using equity method
53
293
Loss (gain) on sale and retirement of property, plant and equipment
0
(90)
Loss (gain) on valuation of investment securities
-
244
Loss (gain) on sale of investment securities
(127)
(1,474)
Decrease (increase) in trade receivables
1,203
(867)
Decrease (increase) in inventories
(2,675)
(2,684)
Increase (decrease) in trade payables
339
(1,539)
Subsidiary-related profit and loss
(1,257)
-
Other, net
(180)
1,562
Subtotal
6,183
5,378
Interest and dividends received
379
391
Interest paid
(51)
(222)
Income taxes paid
(4,026)
756
Net cash provided by (used in) operating activities
2,485
6,303
Cash flows from investing activities
Proceeds from redemption of securities
500
536
Purchase of securities
-
(894)
Purchase of property, plant and equipment
(2,960)
(2,549)
Proceeds from sale of property, plant and equipment
0
166
Purchase of intangible assets
(602)
(325)
Proceeds from sale of investment securities
252
2,074
Purchase of shares of subsidiaries and associates
-
(3,908)
Proceeds from sale of shares of subsidiaries and associates
-
47
Purchase of shares of subsidiaries resulting in change in scope of consolidation
(2,189)
-
Other, net
(1,125)
(901)
Net cash provided by (used in) investing activities
(6,124)
(5,752)
Cash flows from financing activities
Proceeds from long-term borrowings
3,000
3,500
Repayments of long-term borrowings
(4,680)
(1,937)
Net increase (decrease) in short-term borrowings
-
(738)
Net decrease (increase) in treasury shares
0
0
Dividends paid
(1,275)
(1,617)
Other, net
-
(24)
Net cash provided by (used in) financing activities
(2,956)
(818)
Effect of exchange rate change on cash and cash equivalents
(97)
(208)
Net increase (decrease) in cash and cash equivalents
(6,692)
(476)
Cash and cash equivalents at beginning of period
16,738
10,603
Increase in cash and cash equivalents resulting from inclusion of subsidiaries in consolidation
556
-
Cash and cash equivalents at end of period
10,603
10,126
Consolidated Statements of Income
Consolidated Balance Sheets
About ASKA Pharmaceutical Holdings
Top Message
Corporate Philosophy
Company Overview
Charter of Corporate Behavior
Board Members and Corporate Officers
Company Information
Company Information
Organization Chart
Corporate History
Access Map
Policies
Video Library
Media Library
Group Companies
Business Activities
Corporate Message
Digital Transformation
ASKA Pharmaceutical Holdings in Numbers
For Our Shareholders and Investors
Top Message
IR News
IR Library
IR Library
Financial Results and IR Events
Annual Securities Report
Integrated Report
Fact Sheet
Corporate Governance Report (Japanese version only, Related links)
Internal Control Report (Japanese version only, Related links)
Stock and Shareholder Information (Related links)
IR Calendar
Management Strategies and Policies
Management Strategies and Policies
Long-Term Vision ASKA VISION 2035
Medium-Term Management Plan
Pipeline and Intellectual Property
Business Risks
Disclosure Policy
IR Basic Policy
Disclaimer
Governance
Governance
Basic Principles / Corporate Governance Structure
Corporate Governance Basic Policy
Corporate Governance Report (Japanese version only)
Board Members
Compliance / Risk Management
Internal Control System
Internal Control Report (Japanese version only)
Dialogue with Shareholders
Message from Outside Directors
Financial Highlights
Financial Highlights
Performance Review
Performance Highlights
Financial Conditions
Financial Statements
Consolidated Balance Sheets
Consolidated Statements of Income
Consolidated Statements of Cash Flows
Earnings Forecast
ASKA Pharmaceutical Holdings at a glance
ASKA Pharmaceutical Holdings at a glance
Point1 About ASKA - Understanding & History -
Point2 About ASKA - Our Strengths -
Point3 Highly Specialized Product Lineup
Point4 Continuously Evolving R&D
Point5 Stable Shareholder Returns
Frequently Asked Questions
Business Model
ASKA's Management Strategy
Medicine & Body Glossary
IR seminar for Individual Investors
IR Related Information
IR Related Information
IR E-mail Newsletter Service
IR Site Map
Recommended Route to Access Our IR Website
How to Use the IR Site
IR Inquiries
External Evaluation (IR)
Stock and Shareholder Information
Stock and Shareholder Information
Stock Summary Information
Shareholder Information
Shareholders' Meeting
Stock Price Information
Shareholder Return
Stock Procedures (Japanese version only)
Articles of Incorporation and Stock Handling Regulations
Analyst Coverage
Corporate Bonds and Ratings Information
Shareholder Newsletters (Japanese version only)
Privacy Policy (Shareholders)
Sustainability
Our Sustainability
Our Sustainability
Top Commitment
Our Basic Policy for Sustainability
Materiality
Value Creation Process
Capital and Strengths
Initiatives for Sustainability and SDGs
Importance of Female Healthcare and Social Issues
Disclosures based on TCFD recommendations
Disclosures based on TNFD recommendations
Environmental
Environmental
Environmental Management
Disclosures Based on TCFD Recommendations
Disclosures based on TNFD recommendations
Decarbonization Initiatives
Initiatives for Water Resource
Initiatives for Recycle-Oriented Society and Biodiversity
Social
Social
Stakeholder Engagement
Respect for Human Rights
Human capital/Labour Practices
Diversity & Inclusion
Initiatives to Promote the Advancement of Women
Health Management Initiatives
Ethics and Compliance
Supply Chain
Customer Health and Safety
Social Contribution Activities(Community Involvement and Development)
Multi-Stakeholder Policy
Governance (Related Link)
ESG Chart and ESG Data Book
External Evaluation
Initiatives and Member Organizations
Third-party Opinion
Sustainability News
Various Contrasting Tables
Policies (Related Link)
Integrated Report (Related Link)
Press Releases
Contact Us
Privacy Policy
Basic Policy on the Proper Handling of Specific Personal Information, etc.
Terms of Use
Web Accessibility Policy
SNS Community Guidelines
Official website and SNS
Sitemap
Search Results
Important Notice
TOP